Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases.
We believe that no other disease area holds as much need or as much promise for medical breakthroughs as neuroscience. Our focus on Millions of people around the world are affected by multiple sclerosis, Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS). Many people also suffer from less common diseases such as spinal muscular atrophy (SMA) and progressive supranuclear palsy (PSP).
Biogen has some of the world’s best neurologists and neuroscientists. We engage with physicians and scientific leaders around the world with the aim to further medical research. Our focus on neuroscience, our deep scientific expertise and our courage to take risks make us leaders in the research and development of medicines to transform neuroscience to benefit society.
Biogen has pioneered the development of multiple sclerosis (MS) treatments for more than 25 years. We continue to innovate to advance MS treatment and improve outcomes for patients. Our research is focused on potentially transformative therapies, including the potential repair of the damage caused by MS. Our ongoing research into neurodegeneration and nerve repair will help pioneer new therapeutic solutions that may bring us closer to a cure for MS.
Spinal Muscular Atrophy
Previously, individuals with SMA and their families had no treatment options. This changed in December 2016 when Biogen received U.S. Food and Drug Administration (FDA) approval for the first and only therapy approved to treat SMA. The therapy has since been approved in the European Union, Japan, and other regions globally, and has helped thousands of patients around the world to date.
Our world-class neurology research and development organization is pushing towards novel approaches for previously intractable neurodegenerative conditions such as Alzheimer’s disease.We view Alzheimer’s disease as an area where we can make a tremendous difference in the lives of patients.
Biogen Product Portfolio
Below is a list of our company’s marketed products. This information is intended only for U.S. residents.
AVONEX® (interferon beta-1a)
FAMPYRA® (prolonged-release fampridine tablets)
PLEGRIDY® (peginterferon beta-1a)
TECFIDERA® (dimethyl fumarate)